innovative drugs

With nearly 70 years of history, SSY is a leading Chinese maker of tablets, capsules, granules and oral liquids, and was listed on the Hong Kong Stock Exchange in 2005.

FAST NEWS: SSY Group’s profit dips in nine months to September

The Latest: Medical products maker SSY Group Ltd. (2005.HK) reported on Friday its net profit for the first three quarter of this year fell 2.8% year-on-year to HK$919 million ($118 million). Looking…

October 21, 2024

2005.HK

Viva Biotech announced Thursday that the acquisition of 20% of Langhua Pharmaceutical by its Weizongchen Pharmaceutical subsidiary for 640 million yuan has been completed.

FAST NEWS: Viva Biotech completes Langhua Pharma buyout

The latest: Viva Biotech Holdings (1873.HK) announced Thursday that the acquisition of 20% of Langhua Pharmaceutical by its Weizongchen Pharmaceutical subsidiary for 640 million yuan ($87.6 million) has been completed. Looking…

September 22, 2023

Ascletis Pharma announced Tuesday its net loss narrowed sharply in the first half of this year to 16.56 million yuan from an 88 million yuan loss in the same period last year.

FAST NEWS: Ascletis Pharma’s loss narrows as core product sales surge

The latest: Ascletis Pharma Inc. (1672.HK) announced Tuesday its net loss narrowed sharply in the first half of this year to 16.56 million yuan ($2.3 million) from an 88 million…

August 22, 2023

1672.HK

Simcere Pharmaceutical Group Ltd. said on Thursday it expects to report its revenue grew between 24% and 26.3% to between 3.35 billion yuan ($468 million) and 3.41 billion yuan in the first half of 2023.

FAST NEWS: Simcere’s revenue jumps on rising innovative drug sales

The latest: Simcere Pharmaceutical Group Ltd. (2096.HK) said on Thursday it expects to report its revenue grew between 24% and 26.3% to between 3.35 billion yuan ($468 million) and 3.41 billion yuan in…

July 28, 2023

2096.HK

CStone breaks up with drugs partner as U.S. rollout stalls

CStone Pharmaceuticals has pulled out of a licensing deal with EQRx for two innovative cancer drugs but holds onto money already received from its partner Key Takeaways: The companies parted…

May 18, 2023

2616.HK

Fosun Pharma, CanSino take different paths as Covid lift fade

The pair of companies that got strong shots from different Covid vaccines are telling different stories in their latest quarterly results as the pandemic draws down Key Takeaways: Fosun Pharma’s…

May 9, 2023

2196.HK 6185.HK